摘要
AIM: To determine the feasibility and safety of intraluminal brachytherapy in treatment of malignant obstructive jaundice (MOJ) and to evaluate the clinical effect of intraluminal brachytherapy on stent patency and patient survival.METHODS: Thirty-four patients with MOJ were included in this study. Having biliary stent placed, all patients were classified into intraluminal brachytherapy group (group A,n=14) and control group (group B, n = 20) according to their own choice. Intraluminal brachytherapy regimen included: HDR-192Ir was used in the therapy, fractional doses of 4-7 Gy were given every 3-6 d for 3-4 times, and standard points were established at 0.5-1.0 cm. Some patients of both groups received transcatheter arterial chemoembolization (TACE) after stent placement.RESULTS: In group A, the success rate of intraluminal brachytherapy was 98.0%, RTOG grade 1 acute radiation morbidity occurred in 3 patients, RTOG/EORTC grade 1 late radiation morbidity occurred in 1 patient. Mean stent patency of group A (12.6 mo) was significantly longer than that of group B (8.3 mo) (P<0.05). There was no significant difference in the mean survival (9.4 mo vs6.0 mo) between the two groups.CONCLUSION: HDR-^192Ir intraluminal brachytherapy is a safe palliative therapy in treating MOJ, and it may prolong stent patency and has the potentiality of extending survival of patients with MOJ.
AIM:To determine the feasibility and safety of intraluminal brachytherapy in treatment of malignant obstructive jaundice (MOJ)and to evaluate the clinical effect of intraluminal brachytherapy on stent patency and patient survival. METHODS:Thirty-four patients with MOJ were included in this study.Having biliary stent placed,all patients were classified into intraluminal brachytherapy group(group A, n=14)and control group(group B,n=20)according to their own choice.Intratuminal brachytherapy regimen included:HDR^(-192)Ir was used in the therapy,fractional doses of 4-7 Gy were given every 3-6 d for 3-4 times,and standard points were established at 0.5-1.0 cm.Some patients of both groups received transcatheter arterial chemoembolization (TACE)after stent placement. RESULTS:In group A,the success rate of intratuminal brachytherapy was 98.0%,RTOG grade 1 acute radiation morbidity occurred in 3 patients,RTOG/EORTC grade 1 late radiation morbidity occurred in 1 patient.Mean stent patency of group A(12.6 mo)was significantly longer than that of group B(8.3 too)(P<0.05).There was no significant difference in the mean survival(9.4 mo vs6.0 too)between the two groups. CONCLUSION:HDR^(-192)Ir intraluminal brachytherapy is a safe palliative therapy in treating MOJ,and it may prolong stent patency and has the potentiality of extending survival of patients with MOJ.
